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Abstract: Aim: To demonstrate the capabilities of our new capillary electrophoresis – 
mass spectrometry method, which facilitates highly accurate relative quantitation of 
modification site occupancy of antibody-ligand (e.g., antibody-drug) conjugates.  
Background: Antibody-drug conjugates play important roles in medical discovery for 
imaging and therapeutic intervention. The localization and stoichiometry of the 
conjugation can affect the orientation, selectivity, specificity, and strength of molecular 
interactions, influencing biochemical function.  
Objective: To demonstrate the option to analyze the localization and stoichiometry of 
antibody-ligand conjugates by using essentially the same method at all levels including 
ligand infusion, peptide mapping, as well as reduced and intact protein analysis.  
Materials and Methods: Capillary electrophoresis coupled with electrospray ionization 
mass spectrometry was used to analyze the antibody-ligand conjugates.  
Results: We identified three prevalent ligand conjugation sites with estimated 
stoichiometries of 73, 14, and 6% and an average ligand-antibody ratio of 1.37, 
illustrating the capabilities of CE-ESI-MS for rapid and efficient characterization of 
antibody-drug conjugates.  
Conclusion: The developed multilevel analytical method offers a comprehensive way to 
determine the localization and stoichiometry of antibody-drug conjugates for molecular 
medicinal applications. In addition, a significant advantage of the reported approach is 
the small, hydrophilic, unmodified peptides well separated from the neutrals, which is not 
common with other liquid phase separation methods such as LC.  
Keywords: Antibody-drug conjugates, protein small molecule conjugates, CE-MS, stoichiometry, characterization, 
unmodified peptides. 
1. INTRODUCTION 
 Protein-small molecule conjugates (PSMCs) have 
distinct biological specificity and selectivity that make 
them powerful diagnostic tools and therapeutic agents, 
with antibody-drug conjugates (ADCs) as a specific 
example [1-3]. Through either in vivo or in vitro linkage 
of a protein to a small molecule imaging agent, binding 
ligand, or drug, a variety of different biomedical 
functionalities can be created. Some of those 
functionalities include outstanding cytotoxicity in 
parallel with high selectivity, favorable pharmacokinetic 
profile (systemic circulation, enhanced permeability and 
retention) and improved stability. Application of PSMCs  
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as imaging agents holds great potential for precision 
cancer treatment due to their noninvasive and 
quantitative monitoring feature [4]. Antibody-imaging 
agent conjugates are usually dubbed as immuno-
positron emission tomography (PET). Tavare et al. 
published an excellent work about the development of 
an effective immuno-PET method to monitor CD8-
dependent responses to immunotherapy [5], where 
engineered anti-CD8 was linked to 89Zr radiolabel to 
address a challenging cancer immunotherapy problem. 
ADCs, on the other hand, combine the site-specificity 
of a certain monoclonal antibody (mAb) with potential 
anti-cancer effect of a cytotoxic payload [6]. ADCs 
represent a new class of biopharmaceuticals; five have 
already been FDA approved and a few of them are in 
late-phase clinical testing [7]. Furthermore, imaging 
and therapy functions can be utilized simultaneously. 
Adumeau et al. reported a pioneering study about the 
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development of a new methodology that facilitated the 
dual labeling of an antibody with both a toxin and a 
radionuclide [8]. 
 In order to adequately maintain the activity of both 
protein and small molecule, a hydrophilic chemical 
linker often connects the two molecules. The 
stoichiometry of the small molecule on the protein 
affects specificity, selectivity, activity, and toxicity. In 
the case of biotherapeutics, the stoichiometry of the 
conjugate, referred to as drug-to-antibody ratio (DAR), 
is typically measured using UV absorbance and intact 
MS techniques. Similarly, the localization of the small 
molecule on the protein is an important parameter that 
can affect the binding properties of the conjugate. From 
a chemical analysis point of view, PSMCs are 
heterogeneous mixtures of molecules, whose 
complexity poses numerous analytical challenges. 
Such challenges are the determination of the free drug 
level (DAR stability over time most often measured by 
hydrophobic interaction chromatography), investigation 
of the residual solvents (media of the conjugation 
reaction) and the determination of antibody 
aggregation, in which latter has a tendency to increase 
due to the modification of the surface of the antibody 
[9]. Because of the combination of the antibody-, linker-
, and small-molecule chemistry, the complexity of 
PSMCs is much higher than that of any of the individual 
constituents. On the other hand, degradation pathways 
of PSMCs are very similar to those generally observed 
for other antibody based biopharmaceuticals. Physical 
and chemical stability of PSMCs with special emphasis 
on the conjugation process has been comprehensively 
reviewed by Ross and Wolfe [6]. 
 Unlike traditional characterization of either the 
protein or the small molecule components, unique 
challenges arise to appropriately understand the purity 
and stability of the conjugates, as well as the small 
molecule-linker stoichiometry and their localization on 
the protein. Common analytical characterization of 
these protein conjugates by mass spectrometry 
includes intact and reduced mass analysis and peptide 
sequencing with post-translational modification 
identification, considering the small molecule conjugate 
[10-13]. Traditional analyses of either purified or 
synthesized proteins and small molecules are routinely 
and adequately performed by infusion and LC-MS. 
However, the added complexity of linking a protein and 
a small molecule creates additional challenges for 
common LC-MS strategies. In intact mass 
measurements, infusion and protein-compatible LC 
conditions result in co-elution and co-electrospray of 
PSMCs, particularly with the same stoichiometry, but 
different localizations. Co-elution/co-electrospray (ESI) 
during intact MS analysis is also a concern due to 
possible ion suppression and, thus, inaccurate 
estimation of relative stoichiometric ratios [14]. At the 
peptide level, it is difficult to elute using common 
chromatographic resins and elution methods/profiles [9, 
15]. Thus, front-end separation methods for MS 
analysis would aid in the accurate and comprehensive 
characterization of PSMCs. 
 Capillary electrophoresis (CE) is a liquid phase 
analytical technique, well-suited for protein analysis, 
particularly when coupled with mass spectrometry. 
Specifically, capillary zone electrophoresis (CZE) is a 
mode of CE, which allows for separation of proteins 
and peptides in free solution without a stationary 
phase, i.e., only based on their charge and 
hydrodynamic volume ratios. The sensitivity of the 
method has significantly increased with the advent of 
laser induced fluorescence (LIF) detection technique 
[16].Recently, the integration of CE and ESI into a 
single capillary format (CESI) has improved the 
robustness and ionization efficiency to facilitate in-
depth characterization of biomolecules [17-21]. Some 
benefits of antibody drug conjugate analysis by CESI-
MS have already been demonstrated such as the 
quantification of the drug loading values of three drug-
lysozyme conjugates by CESI-MS [22]. In this paper, 
we developed a new CE-ESI-MS method for the intact 
and reduced analysis of localization and stoichiometry 
of model antibody-ligand conjugates.  
2. MATERIALS AND METHODS 
 FITC-PEG-NHS and the Fab domain were 
generated as previously described [23]. FITC-PEG-
NHS was analyzed at 10 mM in 10% acetic acid, pH 
3.1. Fab and Fab-PEG-FITC conjugate peptide 
samples were prepared at 1 mg/mL using a 4-hour 
digestion protocol with RapiGest (Waters, Milford, MA), 
DTT, iodoacetamide, and trypsin (all from Sigma, St 
Louis, MO), then diluted to 250 mg/mL in 125 mM 
ammonium acetate (pH 4.0) as previously described 
[23, 24]. Intact Fab and Fab-PEG-FITC samples were 
prepared at 1 mg/mL in 50 mM ammonium acetate (pH 
4.0). 
 CESI experiments were carried out with a CESI 
8000 system (Sciex, Framingham, MA) equipped with a 
temperature-controlled autosampler and a power 
supply with the ability to deliver up to 30 kV separation 
voltage. A commercial bare fused-silica OptiMS 
capillary cartridge (Sciex) with a porous tip was used 
for the infusion and peptide mapping experiments. N-
(trimethoxysilylpropyl) polyethyleneimine (PEI, Sigma) 
was used to coat the capillary for intact protein 
separations as described in U.S. Patent 6923895. 
Solutions of 10% acetic acid (peptide mapping) and 3% 
acetic acid (reduced and intact analysis) were 
employed as both background electrolytes (BGE) and 
conductive liquids. Pressure injections were used for 
FITC-PEG-NHS infusion (100 psi, 180 sec, capillary 
fill), peptide mapping (5 psi, 60 sec, 50 nL), as well as 
intact and reduced level protein (5 psi, 10 sec, ~8.5 nL) 
analyses. Sample stacking after pressure injection was 
performed by transient isotachophoresis (t-ITP) [24]. 
CESI infusions and separations were performed at 20 
kV, except for the intact analysis using a PEI-coated 
capillary, which employed -20 kV. 
 A TripleTOF® 6600 system with a NanoSpray® III 
source and CESI adapter were used operating at 2 kV 
ion spray voltage (Sciex). MS/MS of the infused FITC-
PEG-NHS molecules were performed from 100 to 1000 
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m/z with a collisional energy of 40 V. Peptide mapping 
was performed with information dependent acquisition 
(IDA) run with 15 MS/MS cycles from 250 to 2000 m/z. 
Intact and reduced protein analysis was performed with 
MS scans from 400 – 4500 m/z. High resolution MS 
and MS/MS spectra were analyzed using 
ProteinPilotTM, PeakView®, and BioPharmaViewTM 
softwares (Sciex) and the Intact Mass analysis 
software from Protein Metrics (Cupertino, CA). 
3. RESULTS 
 A fluorescein isothiocyanate-polyethylene glycol-N-
hydroxysuccinimide (FITC-PEG-NHS) ligand was 
randomly conjugated to primary amines on a fragment 
antigen-binding (Fab) domain at either the protein N-
terminus or the ε-lysine residues (Fig. 1A). The goal of 
the work was to characterize the localization and 
stoichiometry of the random Fab-ligand conjugates for 
structure and activity comparisons with a similar site-
specific Fab-PEG-FITC [23]. Using CESI both as an 
infusion and separation device for mass spectrometric 
analysis, the neat FITC-PEG-NHS and Fab molecules, 
the trypsin-digested peptide conjugates, as well as 
reduced and intact protein conjugates were all 
characterized. 
 Prior to the analysis of the Fab-PEG-FITC 
conjugate, the FITC-PEG-NHS and Fab molecules 
were analyzed individually. Infusion of the FITC-PEG-
NHS molecule by CESI allowed for the identification of 
FITC-PEG-specific signature fragment ions (Fig. 1B) 
used for peptide mapping data analysis. Intact mass 
analysis of the Fab fragment was also performed to 
measure the unconjugated protein and deconvoluted 
mass spectra (Fig. 1C and D). Peptide mapping data 
was generated and the signature FITC-PEG fragment 
ions were then used to extract candidate peptide 
conjugate electrophoretic peaks. Peptide conjugates 
were identified by both high resolution and high mass 
accuracy MS scans and MS/MS scans (Fig. 2) also 
quantified with extracted ion electropherograms (XIEs) 
(Fig. 3). The three most prevalent peptide conjugates 
were found at the heavy chain N-terminus, heavy chain 
lysine 217, and light chain lysine 141 with estimated 
relative abundances of 73, 14, and 6% (Table 1), 
respectively. For the highest abundance N-terminal 
localization, a PEG-only conjugation was also detected 
(1.3%) at a different migration time. Three additional 
lower abundance peptide conjugates were also found 
at 2.4, 0.7, and 0.5% estimated relative abundances. 
 Intact level analysis by CESI-MS facilitated the 
separation of the different stoichiometries of the Fab-
PEG-FITC molecule (Fig. 4A). Due to the CZE 
separation of Fab-PEG-FITC stoichiometric species, 
unique MS spectra (Fig. 4B) and deconvoluted spectra 
 
 
 
Fig. (1). A) General reaction scheme to generate random FITC-antibody conjugates with FITC-PEG4-NHS. (B) MS/MS spectra 
from an infusion of FITC-PEG4-NHS reagent. (C) Intact MS spectra of unconjugated Fab from a separate infusion. (D) 
Deconvoluted mass spectra of the unconjugated Fab. (A higher resolution / colour version of this figure is available in the 
electronic copy of the article). 
4    Current Molecular Medicine, 2020, Vol. 20, No. 00 Fonslow et al. 
 
Fig. (2). Representative (A) extracted ion electropherogram, (B) intact MS spectra, and (C) MS/MS spectra with signature FITC 
and FITC-PEG4 masses for the most abundant FITC-PEG4-EVK peptide. (A higher resolution / colour version of this figure is 
available in the electronic copy of the article). 
 
 
Fig. (3). Representative XIEs for modified and unmodified forms of FITC-PEG4-conjugated peptides used for relative abundance 
estimations in Table 1. (A higher resolution / colour version of this figure is available in the electronic copy of the article). 
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Fig. (4). (A) XIEs of intact Fab-PEG4-FITC masses from the most abundant charge state and isotope as shown in (B). Fab-
PEG4-FITC stoichiometries of zero (blue), one (pink), two (orange), and three (green) are represented in both (A) and (B). (C) 
Deconvoluted mass spectra of mass spectra shown in (B). (A higher resolution / colour version of this figure is available in the 
electronic copy of the article). 
 
(Fig. 4C) could also be generated for each species. 
From the intact MS data, the measured relative 
abundances (12, 38, 36, 13, and 2%) for zero to four 
Fab-ligand stoichiometries from the intact analysis 
were estimated (Table 2), respectively, averaging a 
ligand-Fab ratio of 1.55. 
 
 Reduced analysis by CESI-MS provided additional 
information about the Fab-PEG-FITC stoichiometries 
and structure. For instance, stoichiometry data from the 
reduced analysis (Table III) was consistent with both 
peptide mapping and intact analysis results. The 
majority of FITC-PEG conjugation was found on the 
heavy chain (45.2%) with a stoichiometry of one, 
followed by the light chain (24.5%) stoichiometry of 
one, and heavy chain (16.2%) stoichiometry of two. 
Representative data for the most abundant heavy chain 
single conjugate and light chain without conjugation 
forms are shown in Fig. 5A. Additional analysis of the 
electrophoretic peaks and mass spectra indicated the 
presence of an unknown 14.9 kDa polypeptide (Fig. 
5B, Table 4). 
4. DISCUSSION 
 The peptide mapping and intact measurements 
illustrated some important aspects of both non-specific 
conjugation of ligands and their analyses options, 
particularly with CESI-MS. Spatial resolution of PSMC 
at the intact and reduced levels by CESI-MS was 
complementary and supplementary to similar 
separations and results traditionally achieved at the 
peptide mapping level with LC-MS. While mass 
spectrometry was capable of differentiating the FITC-
PEG stoichiometries on the intact Fab fragment, based 
on mass alone (Δ 607 Da), the CZE-based separation 
facilitated the spatial resolution of the unique 
stoichiometric species prior to electrospray ionization. 
Thus, the generated unique intact and deconvoluted 
mass spectra (Fig. 4B) had a very little contribution in 
other stoichiometric species, indicative of very little co-
migration and co-electrospray. As mentioned earlier, 
this was important since co-electrospray can cause ion 
suppression of lower abundance or less efficiently 
ionized species. Ultimately this should provide a more 
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accurate estimation of stoichiometry and DAR 
information of all fully intact species. 
 In the case of Fab-PEG-FITC conjugates, the CZE-
based separation mechanism was primarily based on 
the change in the isoelectric point or charge of the 
protein in the acidic background electrolyte (BGE). For 
each conjugation of FITC-PEG to a primary amine on 
the Fab, a positive charge was removed from the Fab-
PEG-FITC conjugate. This occurred for each additional 
FITC-PEG molecule added. Additionally, FITC itself 
has a carboxylic acid group, so it can also represent an 
additional negative charge on the Fab-PEG-FITC 
molecules under certain pH conditions. While this was 
most important to the intact protein analysis, the same 
separation mechanism applied to the reduced and 
peptide mapping analyses performed. In the case of 
peptide mapping data, the mobility shifts caused by the 
addition of a FITC-PEG molecule to a peptide were 
much greater (Fig. 3) since the charge to hydrodynamic 
volume ratio was also much greater for a peptide over 
an intact protein. For the peptides, the mobility shift 
was anywhere from four to eight minutes. The CZE 
separation was also capable of separating the PEG-
only modified EAK peptide (Fig. 3B). Separation and 
identification of this peptide were particularly notable 
since (1) traditional peptide mapping by LC-MS would 
not retain or separate these species since they are very 
small and hydrophilic and (2) it could not be attributed 
to any ESI- or MS-based loss of FITC due to the large 
spatial resolution between the different EAK peptide 
forms. Thus, the PEG-only modified peptide would be 
indicative of loss of FITC from either the FITC-PEG-
NHS reagent before or during the labeling reaction or 
loss of the FITC after the conjugation step. In the case 
of a therapeutic ADC, this would represent the loss of 
the drug payload. 
 The CZE-based separation mechanism of the 
different species in solution was beneficial prior to ESI 
and MS detection of the Fab-PEG-FITC species for 
additional reasons. For example, the Fab-PEG-FITC 
stoichiometry was only detected at 2.2% relative 
abundance. It is unlikely that this low abundant form 
 
Fig. (5). Results from reduced analysis of Fab-PEG4-FITC. (A) XIEs and (B) intact mass spectra of Fab light chain (blue) and 
Fab-PEG-FITC heavy chain (pink). Deconvoluted mass spectra of (C) Fab light chain and (D) Fab-PEG-FITC heavy chain. (E) 
XIE, (F) intact mass spectra, and (G) deconvoluted mass spectra of unexpected polypeptides. (A higher resolution / colour 
version of this figure is available in the electronic copy of the article). 
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would have been detected accurately if co-
electrosprayed with more abundant forms using either 
infusion or a co-eluting LC-MS strategy. Additionally, 
closer inspection of the intact Fab-PEG-FITC 
electrophoretic peaks (Fig. 4A) indicated that the peaks 
both broadened and split at higher stoichiometric ratios. 
In order to explain this phenomenon, the random 
nature of the conjugations must be considered. Since 
the conjugation to lysine residues is random and varies 
in abundance (Table 1), it would be expected that 
different combinations and efficiencies of FITC-PEG 
conjugations would create many different intact forms. 
For a Fab-PEG-FITC stoichiometry of one, there 
appear to be three partially unresolved peaks. This was 
consistent with three conjugation sites detected by 
peptide mapping at ~10% and greater relative 
abundance. Similarly, considering the eight detected 
conjugations peptides, for a Fab-PEG-FITC 
stoichiometry of two, there are 28 or 256 different 
possible intact forms. However, since only two peptides 
were detected at greater than 25% abundance (Table 
1), it was likely that there could be 22 (i.e., four) 
abundant intact Fab-PEG-FITC forms. Indeed, upon 
inspection of the electrophoretic peak profiles in Fig. 
4A, there could be at least three partially unresolved 
intact forms. Finally, for a Fab-PEG-FITC stoichiometry 
of three, there are likely 32 (i.e., 9) possible conjugation 
combinations again from the two conjugated peptides 
detected at about 25% relative abundance. Inspection 
of the electrophoretic peak associated with a 
stoichiometry of three indicated the partial resolution of 
5 – 6 peaks, also consistent with the expected number 
of combinations. This interpretation of the intact forms 
was also supported by the reduced level analysis. The 
extracted electrophoretic peak for the Fab-PET-FITC 
heavy chain stoichiometry of one is shown in Fig. 4A. 
As expected from the peptide mapping and intact 
analysis relative abundance measurements (Table 1 & 
2), there is one abundant form with at least two lower 
abundant forms present just for the HC Fab-PEG-FITC 
stoichiometry of one. Relative abundance measure-
ments for all the different reduced Fab-PEG-FITC 
forms (Table 3) further supported the relative 
abundance and stoichiometry measurements made 
using peptide mapping and the intact analysis. 
Therefore, this data collectively shows that CESI-MS is 
well-suited for the peptide mapping, reduced, and intact 
level analysis of conjugated proteins, particularly when 
relative quantitation is of high importance. 
 Another notable advantage of using CESI-MS over 
traditional LC-MS methods is that very similar 
separation conditions can be used for small peptides (< 
1 kDa) up to intact mAbs (~150 kDa). This capability is 
illustrated herein by the usage of BGEs only differing in 
acetic acid concentration (3% versus 10%). For this 
reason, in either the peptide mapping, reduced or intact 
level analysis was possible to detect polypeptides of 
various sizes in the same analysis. Expected results of 
the reduced analysis of the Fab-PEG-FITC analysis are 
shown in Fig. 5A-D where the heavy and light chains 
are both present and their masses add up to the intact 
Fab-PEG-FITC mass. However, notably an abundant 
unknown 14.9 kDa polypeptide was detected only in 
the reduced level analysis (Fig. 5E-G). Additional lower 
abundance polypeptides of 15.5, 16.2, and 16.4 kDa 
were also detected at the same electrophoretic 
migration time (Fig. 5G). The lack of detection in the 
intact level implies the unknown polypeptide arose from 
a disulfide-linked form of the Fab fragment. The 
presence of this additional polypeptide may be best 
explained by the peptide mapping data. Two of the 
eight Fab-PEG-FITC peptides (Table 1, peptides 
MNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSV
TVSSASTKGPSVFPLAPSSK and HYYYGGSYAM 
DYWGQGTSVTVSSASTK) were identified with C-
terminal lysine conjugation with FITC-PEG. This would 
not be expected on a full-length heavy chain since 
trypsin is unable to cleave modified lysine residues [25, 
26]. Thus, a probable explanation for the presence of 
these peptides is unexpected C-terminal lysine 
processing prior to the conjugation reaction. Both 
lysine-conjugate residues are near the middle of the 
Table 1. List of identified FITC-PEG-peptides and PEG-peptides from peptide mapping. 
Chain Modified amino acid and sequence FITC-PEG relative abundance* 
PEG relative 
abundance* 
Heavy E1, EVK 73.3% 1.3% 
Heavy 
K97, K124, & K136 
MNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSASTKGP 
SVFPLAPSSK 
27.8% 27.8%# 
Heavy K217, KVEPK 14.4% Not detected 
Light K141, EAKVQWK 6.1% Not detected 
Heavy K124, HYYYGGSYAMDYWGQGTSVTVSSASTK 3.3% Not detected 
Light K31, ASQDISKYLNWYQQKPDGTV 2.4% Not detected 
Light K188, ADYEKHK 0.7% Not detected 
Light K207, VYACEVTHQGLSSPVTKSFNRGE 0.5% Not detected 
*Relative abundances were calculated by dividing summed peak areas of modified peptides by summed peak areas of all associated peptide 
sequences at different charge states. PEG and FITC-PEG relative abundance are the same since both were detected on the same peptide. 
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heavy chain (K124 and K136 out of 228 residues). 
Notably, the theoretical masses of the N-terminal heavy 
chain polypeptides truncated at K124 and K136 are 
13.6 and 14.8 kDa, respectively. The 14.8 kDa 
theoretical mass (Table 4) is strikingly similar to the 
14.9 kDa measured mass (Fig. 5G and Table 4). 
Additionally, other lower abundant masses of 15.5, 
16.2, and 16.4 kDa correlate well with anticipated 
masses of the conjugated forms of the hypothesized 
14.9 kDa polypeptide (Fig. 5G and Table 4). Further, 
MS/MS characterization of the 14.9 kDa polypeptide 
and lower abundance modified forms would be needed 
to confirm this hypothesis. 
Table 2. Estimation of Fab-ligand stoichiometries from 
intact analysis. 
No. of FITC-PEG per Fab Peak Areas* % Peak Area 
0 6.17 x 103 11.8% 
1 1.98 x 104 37.9% 
2 1.85 x 104 35.5% 
3 6.55 x 103 12.6% 
4 1.16 x 103 2.2% 
*Peak areas were calculated by summing the signal for all associated 
charge states for each Fab-PEG-FITC stoichiometry using the 
Analyst software (Sciex). 
 
Table 3. Estimation of Fab-ligand stoichiometries from 
reduced analysis. 
No. of FITC-PEG per 
Fab chain 
Peak Areas* % Peak Area 
Heavy (0) 1.23 x 103 38.6% 
Heavy (1) 1.44 x 103 45.2% 
Heavy (2) 5.15 x 102 16.2% 
Light (0) 9.75 x 103 75.5% 
Light (1) 3.17 x 103 24.5% 
*Peak areas were calculated by summing the signal for all associated 
charge states for each Fab-PEG-FITC stoichiometry. 
 
Table 4. Comparison of measured and theoretical 
masses for truncated heavy chain species. 
Heavy chain C E1 - K136 
modifications 
Theoretical mass Measured 
mass 
None 14819.75 14912.00 
FITC-PEG 15426.91 15520.56 
2 FITC-PEG 16034.07 16170.76 
2 FITC-PEG + PEG 16252.20 16373.51 
 
 These types of in-depth considerations with higher 
separation resolving power are important not only for 
the experiments described herein, but also for the 
analysis of other lysine-conjugated or non-specifically 
conjugated ligands on other protein and antibody 
conjugates used as diagnostics and therapeutics. 
Collectively, these results illustrate the capabilities of 
CESI-MS for the characterization of antibody-ligand 
conjugates with a multi-functional workflow at the small 
molecule, peptide, reduced, and intact protein levels. 
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CESI = capillary electrophoresis electrospray 
ionization 
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mAb = monoclonal antibody 
DAR = drug-to-antibody ratio 
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PEG = polyethylene glycol  
FITC = fluorescein isothiocyanate 
Fab = fragment antigen-binding  
XIE = extracted ion electropherogram 
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